Billion To One
Back to full portfolio
BillionToOne is a molecular diagnostics company. It builds tests spanning prenatal screening and oncology, from fetal risk assessment for single-gene conditions and aneuploidy to therapy selection and treatment response monitoring, on a platform built around counting individual DNA molecules. That counting yields tests designed to resolve single base-pair changes from a blood draw and return answers early enough to inform care.
FOUNDER(S)
Oguzhan Atay, PhD and David Tsao, PhD
LEADERSHIP
Oguzhan Atay, PhD and David Tsao, PhD
BillionToOne is a molecular diagnostics company. It builds tests spanning prenatal screening and oncology, from fetal risk assessment for single-gene conditions and aneuploidy to therapy selection and treatment response monitoring, on a platform built around counting individual DNA molecules. That counting yields tests designed to resolve single base-pair changes from a blood draw and return answers early enough to inform care.
